卵巢子宫内膜异位症及后续诊断的卵巢癌中的基因组改变
该研究对瑞典两所大学医院1998-2016年间有子宫内膜异位症手术史且随后发生卵巢癌的11例配对样本进行全外显子测序,发现所有配对样本共享至少一个体细胞突变,但癌症相关基因的相同突变从未在后续癌中观察到,提示卵巢癌并非起源于具有癌样遗传特征的子宫内膜异位症,但可能存在共同前体。
要点
- 所有配对样本均存在一个或多个共享体细胞突变,支持共同细胞起源。
- 子宫内膜异位症中常见的癌症相关基因非沉默突变未在后续癌中观察到。
- 克隆优势程度与癌诊断时间呈正相关(Spearman's rho 0.853,P < 0.001)。
核心结论
- 数据提示卵巢癌并非起源于具有癌样遗传特征的卵巢子宫内膜异位症,但共同前体是可能的。
- 子宫内膜异位症中多年前的癌症相关突变与恶性转化不直接相关,而 resilient 卵巢子宫内膜异位症可能延迟肿瘤发生。
- 影响免疫反应的遗传改变是早期且重要的事件。
研究设计与样本
- 瑞典两所大学医院的病理生物样本库被审查,以识别1998-2016年间手术切除子宫内膜异位症后发生卵巢癌的女性。
- 仅45例存档病例被识别,经病理审查排除25例(9例重新分类为非子宫内膜异位症相关卵巢癌,16例无法确认卵巢子宫内膜异位症),因组织不足或DNA质量差排除9例,最终11例有满意DNA eligible进一步分析。
- 对11例子宫内膜异位症和11例癌进行激光捕获显微切割或宏切割收集上皮细胞并提取DNA,5例FFPE正常组织或6例癌症诊断时血液作为种系对照,共33样本进行全外显子测序。
主要发现
- 子宫内膜异位症手术中位年龄42岁,后续卵巢癌诊断中位年龄54岁,两者中位时间间隔10(7-30)年。
- 所有配对样本均存在一个或多个共享体细胞突变。
- 子宫内膜异位症中癌症相关基因的非沉默突变频繁,但相同突变从未在后续癌中观察到。
- 变异等位基因频率显示的克隆优势程度与癌诊断时间呈正相关(Spearman's rho 0.853,P < 0.001)。
- 与免疫逃逸相关的基因突变在配对样本间最为保守,这些基因区域在两种样本类型中常受拷贝数改变影响;所有病例的突变负荷和突变特征提示DNA修复机制缺陷。
临床怎么用
- 原文未据此给出推荐。
局限性
- 尽管1998-2016年间定位了数千例手术切除的子宫内膜异位症,仅45例配对样本被识别,更少(11例)符合测序条件。
- 两组(子宫内膜异位症和癌)中观察到的高水平内和间异质性支持对所声称的遗传关联进行进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can the alleged association between ovarian endometriosis and ovarian carcinoma be substantiated by genetic analysis of endometriosis diagnosed prior to the onset of the carcinoma? SUMMARY ANSWER: The data suggest that ovarian carcinoma does not originate from ovarian endometriosis with a cancer-like genetic profile; however, a common precursor is probable. WHAT IS KNOWN ALREADY: Endometriosis has been implicated as a precursor of ovarian carcinoma based on epidemiologic studies and the discovery of common driver mutations in synchronous disease at the time of surgery. Endometrioid ovarian carcinoma and clear cell ovarian carcinoma are the most common endometriosis-associated ovarian carcinomas (EAOCs). STUDY DESIGN, SIZE, DURATION: The pathology biobanks of two university hospitals in Sweden were scrutinized to identify women with surgically removed endometrioma who subsequently developed ovarian carcinoma (1998-2016). Only 45 archival cases with EAOC and previous endometriosis were identified and after a careful pathology review, 25 cases were excluded due to reclassification into non-EAOC (n = 9) or because ovarian endometriosis could not be confirmed (n = 16). Further cases were excluded due to insufficient endometriosis tissue or poor DNA quality in either the endometriosis, carcinoma, or normal tissue (n = 9). Finally 11 cases had satisfactory DNA from all three locations and were eligible for further analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: Epithelial cells were collected from formalin-fixed and paraffin-embedded (FFPE) sections by laser capture microdissection (endometrioma n = 11) or macrodissection (carcinoma n = 11) and DNA was extracted. Normal tissue from FFPE sections (n = 5) or blood samples collected at cancer diagnosis (n = 6) were used as the germline controls for each included patient. Whole-exome sequencing was performed (n = 33 samples). Somatic variants (single-nucleotide variants, indels, and copy number alterations) were characterized, and mutational signatures and kataegis were assessed. Microsatellite instability and mismatch repair status were confirmed with PCR and immunohistochemistry, respectively. MAIN RESULTS AND THE ROLE OF CHANCE: The median age for endometriosis surgery was 42 years, and 54 years for the subsequent ovarian carcinoma diagnosis. The median time between the endometriosis and ovarian carcinoma was 10 (7-30) years. The data showed that all paired samples harbored one or more shared somatic mutations. Non-silent mutations in cancer-associated genes were frequent in endometriosis; however, the same mutations were never observed in subsequent carcinomas. The degree of clonal dominance, demonstrated by variant allele frequency, showed a positive correlation with the time to cancer diagnosis (Spearman's rho 0.853, P < 0.001). Mutations in genes associated with immune escape were the most conserved between paired samples, and regions harboring these genes were frequently affected by copy number alterations in both sample types. Mutational burdens and mutation signatures suggested faulty DNA repair mechanisms in all cases. LARGE SCALE DATA: Datasets are available in the supplementary tables. LIMITATIONS, REASONS FOR CAUTION: Even though we located several thousands of surgically removed endometriomas between 1998 and 2016, only 45 paired samples were identified and even fewer, 11 cases, were eligible for sequencing. The observed high level of intra- and inter-heterogeneity in both groups (endometrioma and carcinoma) argues for further studies of the alleged genetic association. WIDER IMPLICATIONS OF THE FINDINGS: The observation of shared somatic mutations in all paired samples supports a common cellular origin for ovarian endometriosis and ovarian carcinoma. However, contradicting previous conclusions, our data suggest that cancer-associated mutations in endometriosis years prior to the carcinoma were not directly associated with the malignant transformation. Rather, a resilient ovarian endometriosis may delay tumorigenesis. Furthermore, the data indicate that genetic alterations affecting the immune response are early and significant events. STUDY FUNDING/COMPETING INTEREST(S): The present work has been funded by the Sjöberg Foundation (2021-01145 to K.S.; 2022-01-11:4 to A.S.), Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (965552 to K.S.; 40615 to I.H.; 965065 to A.S.), Swedish Cancer Society (21-1848 to K.S.; 21-1684 to I.H.; 22-2080 to A.S.), BioCARE-A Strategic Research Area at Lund University (I.H. and S.W.-F.), Mrs Berta Kamprad's Cancer Foundation (FBKS-2019-28, I.H.), Cancer and Allergy Foundation (10381, I.H.), Region Västra Götaland (A.S.), Sweden's Innovation Agency (2020-04141, A.S.), Swedish Research Council (2021-01008, A.S.), Roche in collaboration with the Swedish Society of Gynecological Oncology (S.W.-F.), Assar Gabrielsson Foundation (FB19-86, C.M.), and the Lena Wäpplings Foundation (C.M.). A.S. declares stock ownership and is also a board member in Tulebovaasta, SiMSen Diagnostics, and Iscaff Pharma. A.S. has also received travel support from EMBL, Precision Medicine Forum, SLAS, and bioMCC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
引用
- Linder A, Westbom-Fremer S, Mateoiu C, et al. Genomic alterations in ovarian endometriosis and subsequently diagnosed ovarian carcinoma. Hum Reprod. 2024. PMID: 38459814. doi:10.1093/humrep/deae043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。